chrisvoncsefalvay/vaers-outcomes huggingface dataset:
I had a headache, chills and fatigue for about two days after receiving the vaccine. On 12/29/2022 I developed a sore throat, very tired, cough with a lot of phlegm. I had laryngitis for a week. I went to the doctor on 01/06/2023 and was tested very COVID-19 and strep was all negative. I had an unknown respiratory virus from 12/29/2022 to 01/17/2023. I was not given a prescription but advised to take over the counter meds to help with symptoms. I recently had an episode with difficulty swallowing. I went to the urgent clinic and received a prescription for omeprazole.
Medical assistant reporting AE for improperly stored vaccine administered. No additional AE information reported. No PQC reported. See case 02244271.     ?    Names of vaccines involved: PROQUAD (U039955 11/03/2022)    ?    Temperature: 9.3F; Temperature: 9.3F; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender.  The patient's pertinent medical history, current conditions, drug reactions or allergies and concomitant medications were not reported.  On 01-SEP-2022, the patient was vaccinated with one dose of measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) subcutaneous injection, lot #U039955, expiration date: 14-JUN-2023, administered for prophylaxis (strength, site, and route of administration were not provided) after temperature excursion (9.3 degrees Fahrenheit (F) for 0 hour 5 minutes 0 seconds and 14 degrees F up to 46 degrees F (25.9 F) for 1 hour 20 minutes 0 seconds) (product storage error). No additional adverse events details or product quality complaints were reported (no adverse event).
On 12/21/2020 at 1630,  patient  complained of anxiousness, feeling hot, and claustrophobia about 8-10 minutes S/P COVID 19 Vaccine administration.
This incident was reported by the patient, not the nurse, as the reaction happened several hours after the injection: "Yesterday I received a flu shot here at around 4:15. My vaccine lot number is 00844611A. 7:30 last night I was in the ER with my throat swelling up, I couldn't swallow. I felt better after receiving steroids and BENADRYL and went home around 11:45 pm." The ER the patient went to is unknown, but the patient can be contacted if that information is needed.
This case was reported by a consumer via call center representative and described the occurrence of influenza like illness in a male patient who received SHINGRIX for prophylaxis. In April 2018, the patient received SHINGRIX. On an unknown date, less than a year after receiving SHINGRIX, the patient experienced influenza like illness. On an unknown date, the outcome of the influenza like illness was unknown. It was unknown if the reporter considered the influenza like illness to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The patient's concomitant product included AMBIEN as needed for sleep. The reporter volunteered at a free medical clinic. She said one of the physicians who volunteer told her that, he felt like he had the flu following his SHINGRIX vaccination. The reporter thought that, the patient received the SHINGRIX vaccine around April 2018 but was not sure. The reporter declined to answer any questions. She said she would tell the physician to contact GlaxoSmithKline to report his symptoms and further related details. The reporter would not answer questions because she had not got the physician's permission, and it was unknown if she granted permission to be contacted by GSCP because she said she would prefer the physician to call GlaxoSmithKline himself and that she did not want to report on his behalf without his permission. No further details provided. This case has been linked with case US2018117635, rpeorted by the same reporter.
A female patient developed lymph node swelling in her armpit following treatment with RabAvert for post exposure therapy. The physician started the series in a patient who received the second dose three days ago (date not given). Within 48 hours of the second dose, she developed lymph node swelling in the armpit of the deltoid used for immunization. There were no other associated localized or systemic symptoms. There were also no symptoms of hypersensitivity, allergy or neurologic complications. The physician assessed the event as possibly realted to the RabAvert therapy.
Sharp Chest pain; Conclusion was allergic to something in vaccine; Dose Number:2, 06Aug2021/ Dose Number:1, 02Jan2021; felt like she would die/was not herself; Shortness of breath; Chest tightness; Unable to lie down to sleep; Brain fog; Marked fatigue months; weakness; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient. Other Case identifier(s): US-PFIZER INC-202200398207 (Pfizer).  A 67 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 06Aug2021 11:00 (Lot number: ew0164) at the age of 67 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "hypertension" (unspecified if ongoing); "hypothyroid" (unspecified if ongoing); "nonhodgkins lymphoma" (unspecified if ongoing). Concomitant medication(s) included: LEVOTHYROXINE taken for thyroid disorder; VALSARTAN & HCTZ; NEXIUM [ESOMEPRAZOLE SODIUM]. Vaccination history included: Bnt162b2 (Dose Number: 1, Batch/Lot No: el3246, Location of injection: Arm Right, Vaccine Administration Time: 11:00 AM, Route of Administration: Intramuscular), administration date: 02Jan2021, when the patient was 66 years old, for COVID-19 immunization. The following information was reported: ANXIETY (non-serious), outcome "recovered", described as "felt like she would die/was not herself"; INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (non-serious) with onset 06Aug2021, outcome "unknown", described as "Dose Number:2, 06Aug2021/ Dose Number:1, 02Jan2021"; CHEST PAIN (non-serious), outcome "recovered", described as "Sharp Chest pain"; DYSPNOEA (non-serious), outcome "recovered", described as "Shortness of breath"; CHEST DISCOMFORT (non-serious), outcome "recovered", described as "Chest tightness"; SLEEP DISORDER (non-serious), outcome "recovered", described as "Unable to lie down to sleep"; FEELING ABNORMAL (non-serious), outcome "recovered", described as "Brain fog"; FATIGUE (non-serious), outcome "recovered", described as "Marked fatigue months"; ASTHENIA (non-serious), outcome "recovered", described as "weakness"; ALLERGY TO VACCINE (non-serious), outcome "recovered", described as "Conclusion was allergic to something in vaccine". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of anxiety, chest pain, dyspnoea, chest discomfort, sleep disorder, feeling abnormal, fatigue, asthenia, allergy to vaccine.
it has been painful; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of pain in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On 24-MAR-2023, the patient received Shingles vaccine. In MAR-2023, an unknown time after receiving Shingles vaccine, the patient experienced pain (Verbatim: it has been painful). The outcome of the pain was not reported.   It was unknown if the reporter considered the pain to be related to Shingles vaccine.   It was unknown if the company considered the pain to be related to Shingles vaccine.   Additional Information: GSK Receipt Date: 27-MAR-2023 This case was reported by a patient via interactive digital media. The patient just got the shingles last shot on Friday and it had been painful. The patient hoped that he/she did not get it. The patient could not handle the pain and stated that nobody could.  The follow up would not possible as no contact details were available.
Encephalopathy within 7days of DTAP. (See attached). Early AM of 11/6, he spiked a fever of 38.4C. He was noted to be bradycardic during the blood draw but recovered immediately. He was also noted to have apnea lasting up to 20 seconds, associated with desats down to high 80's while on O2. At 13:30, RN responded to apnea alarm. He was not breathing and sats were down to 50's. He was stimulated and MD was called. He continued to be apneic, by this time sats down to 30's with dusky color. HR remained over 140's. Decision was made to send him to PICU. He had IV placed and during which time he was given CPAP via bagging, 0.4mg of MSO4 given, intubation was 1st attempted by resident MD with attending supervision. After placement of ETT, we were unable to hear good breath sounds and pt had poor color, so tube was pulled, NG place, pt continued to be bagged back to 100%. No epinephrine was given (HR recovered by the time epi was drawn up). After this report was prepared, I was called back into the pt's room, because he became tonic with mouth movements. Was given valium and pt's extremities relaxed. At about the same time, his BP was found to be low, MAPs 30-40. NS bolus of 20/kg given. On 60-day followup: pt was transferred to ICU where he got slightly better, then worse again. He died 12/2000. The pt was medically fragile and because his decompensation occurred after DTAP I reported it. Believes his decompensation is multifactorial and not related to vaccines alone.
After the second Pfizer vaccine I experienced a very painful menstrual period in-between my cycle. My period had just ended on 8/25 and should not begin until 9/18. The period itself was not super heavy but extremely painful almost contraction like. I have reported this to my primary doctor and I will follow up with my Gyno.  Nothing about this seems normal to me so I felt I needed to report this.
A report has been received from a Pharmacist concerning a 7 year old, Male subject, who had been receiving FLUMIST QUADRIVALENT (intranasal). FLUMIST QUADRIVALENT started on 05-Jan-2014. Pharmacist reported that on 05-Jan-2014, they inadvertently administered two doses of expired FLUMIST QUADRIVALENT. Not reporting any symptoms. The outcome of the event of expired FLUMIST QUADRIVALENT is unknown. The report was considered to be non-serious by reporter.
A report has been received from a Physician concerning a 7 year old, Female subject, who had been receiving Nasal FLUMIST, 0.2 Millilitres, Once/Single administration and Unknown NOSTRIL. FLUMIST started on 14-Sep-2012 and NOSTRIL started on an unknown date. The patient experienced CONGESTION which started on 14-Sep-2012. The outcome of the event of CONGESTION is unknown. The report was considered to be non-serious. Summary of insignificant follow-up information received by AstraZeneca/MedImmune on 24-Oct-2012: new primary reporter added, details of Administered by and Responsible physician reporter details updated. Corrected Report 24-Oct-2012: patient and responsible physician reporter records added, Have you reported this adverse event previously field amended, Form Completed by and Relation to Patient fields completed, start date of FLUMIST added, action taken corrected, event onset date added, narrative updated.
I started loosing hair and  bald spots starting in May.  By June I had additional large bald spots .  I have no previous history with hair loss with myself or family.  In June went to dermatologist and diagnosed with alopetia areata. No history with COVID - previous 3 tests negative.  Thyroid tests and Iron and blood test normal.
Lower abdominal cramping, constipation, dizziness and nauseous for over 3 months without stopping.
This spontaneous report as received from a pharmacist via company representative refers to a female patient of unknown age. The patient had suffered from recurring shingles outbreaks. On an unknown date, the patient was vaccinated with a dose of ZOSTAVAX (dose, route, lot number not reported). On an unknown date, the patient experienced another outbreak of shingles. The outcome of outbreak of shingles was unknown. The relatedness between adverse event and therapy with ZOSTAVAX was not reported. Additional information has been requested.
Approximately October 1998, pt was vaccinated with one dose of varicella. On June 8, 1999 the pt began to develop lesions predominantly on her left forehead above the eyebrow and temporal area. Over the next several days, new lesions continued to develop, extending approximately 2 inches into her hair line. No temperature was taken because pt did not feel warm, he felt afebrile. Also reported the pt experienced irritability, anorexia, and regression in some of her behavior (ie: not verbalizing the alphabet or words as she had done previously, wanting her pacifier and blankie, which she hadn't used recently, etc.) The MD did not know if this behavioral change was just due to her not feeling well, or to some other factor. The reporting physician noted that he add his wife (also a physician) dx'd their daughter as having herpes zoster. Additionally, they spoke with their pediatrician by phone, who prescribed acyclovir to treat the lesions. The pt was never actually seen by her pediatrician. A scab from the pt forehead lesions was sent off for PCR analysis. The physician noted that this is one of her last scabs and that as for now, all of the scabs are heeled. Additionally, it was noted that some hyperpigmentation occured in the area where the lesions were.
about 5-10 minutes after receiving vaccine (patient's first dose) patient started to slouch/slide in her seat.  She never lost consciousness but was non-verbal, only moaning, shivering and crying. EMS was immediately contacted and arrived to the scene.  Her blood glucose was  checked by EMS and was 52.  She was given fluids via IV and recovered shortly after.
Last physical 9/17/04. Nasal O2, alert. Last PRRS, S2, no murmur. 10/15 temporary episode of respiratory distress. 10/18 Fever 100.5; no coughing. 10/23 Fever 100.5, responsive, given O2; fever broke late morning. 10/24 Fever 102.2. 10/23 fever 102.4, rapid breathing; on O2, no respiratory distress. Died at 21:00. Death Certificate received on 11/16/2004 states cause of death is end-stage dementia. 11/2/04 Received medical records from PCP which revealed patient with multiple complex medical problems including late stage Alzheimers.
Systemic: Dizziness / Lightheadness-Mild, Systemic: Fainting / Unresponsive-Mild, Systemic: Flushed / Sweating-Mild, Systemic: Seizure-Mild, Systemic: Shakiness-Mild, Additional Details: patient indicated prior to vaccination that she ususally faints when given shots. we discussed what to expect from vaccination and that i would be right in front w her. I administered the vaccine and she seemed relieved that it was painless. i had her sit down in front of the pharmacy and about 5 min later she alerted me that she felt faint. i stood in front of  her and aked her to put her head down when she collapsed in my arms , was sweating, pale and began to shake, possiby a seizure
Achy; Fatigue; 100 degree Fahrenehit fever; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Achy), FATIGUE (Fatigue) and PYREXIA (100 degree Fahrenehit fever) in a 73-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 24M20A and 039K20A) for COVID-19 vaccination.     Concurrent medical conditions included Seasonal allergy (seasonal allergies), Immunocompromised and Immune thrombocytopenia (no change in recent status such as improvement or worsening) since 1996. Concomitant products included PREDNISONE, MULTIVITAMINS [VITAMINS NOS] and CALCIUM for an unknown indication.   On 30-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Feb-2021, the patient experienced PAIN (Achy), FATIGUE (Fatigue) and PYREXIA (100 degree Fahrenehit fever). The patient was treated with PARACETAMOL (TYLENOL [PARACETAMOL]) for Fever, Fatigue and Ache, at an unspecified dose and frequency. On 01-Mar-2021, PAIN (Achy), FATIGUE (Fatigue) and PYREXIA (100 degree Fahrenehit fever) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-Feb-2021, Body temperature: 100 degree fahreneheit (High) 100 degree Fahreneheit : fever.         The patient did not undergo any COVID test or never been diagnosed with COVID disease before.   This case was linked to MOD-2022-498720, MOD-2022-498874 (Patient Link).
Reacted same day vaccines given.  Red, hot to touch, fever, diarrhea.  Area hard, tender to touch.  Looks like a large hive.
Dizzy and lightheaded several minutes after receiving injection. EMT intervened to take blood pressure and pulse. Dizziness, brain fog, heart palpitations, and extreme fatigue lingering ever since.
Patient presented to primary care clinic for routine follow up and requested COVID bivalent booster.  Denied having had a booster within the last year.  Patient completed vaccine registration form and vaccination was administered.  Admin staff proceeded to log vaccine and noted that a Pfizer bivalent booster vaccination was already logged as being administered on 9/27/2022 at an outside facility.  A staff member here called patient to discuss this and patient adamantly denied having had a booster prior to this date.  Our office contacted the outside facility listed as the vaccinator and they confirmed there was supporting documentation showing she was vaccinated on 9/27/2022 at their facility.
Pt. presented to clinic Aug. 04/09 - Symptoms had started 2 days prior - fever, chills, cough. PE - (+) Left lower lobe rales - treated with BIAXIN XL, Albuterol.
infected with COVID-19 virus; This spontaneous report has been received from a pharmacist referring to a female of unknown age.  The patient's pertinent medical history, concomitant therapies and drug allergy or reactions were not reported.  On an unknown date, the patient received the first dose of varicella virus vaccine live (oka/merck) (VARIVAX) (formulation, lot#, expiration date, strength, dose, frequency and route of administration were not reported) for prophylaxis.   After the first dose, on an unknown date, the patient was infected with coronavirus disease 2019 (COVID-19) virus. On an unknown date, the patient recovered from the event. The patient did not receive the second dose yet.  The causal relationship between the event and varicella virus vaccine live (oka/merck) (VARIVAX) was not provided.
First Dose on 17-Jan-2021 and 2nd Dose on 27-Feb-2021; a little soreness in the arm; fatigue; Body aches; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (a little soreness in the arm), FATIGUE (fatigue), MYALGIA (Body aches) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First Dose on 17-Jan-2021 and 2nd Dose on 27-Feb-2021) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination.     No Medical History information was reported.   On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Feb-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First Dose on 17-Jan-2021 and 2nd Dose on 27-Feb-2021). On an unknown date, the patient experienced PAIN IN EXTREMITY (a little soreness in the arm), FATIGUE (fatigue) and MYALGIA (Body aches). At the time of the report, PAIN IN EXTREMITY (a little soreness in the arm), FATIGUE (fatigue) and MYALGIA (Body aches) had resolved and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (First Dose on 17-Jan-2021 and 2nd Dose on 27-Feb-2021) outcome was unknown.            No Concomitant product use was reported.  The patient had no side effects after the first shot and following the second shot the patient had a little soreness in the arm, fatigue, and body aches for about 24 hours.  No treatment information was reported.   This case was linked to MOD-2022-555093 (Patient Link).
Within 15-minutes of vaccination, the patient reported feeling flush, near-syncopal, dizzy, and lightheaded with diaphoresis. EMS evaluated patient on-site. Patient was hypotensive (89/60). 12-lead EKG showed sinus tachycardia, rate 102 bpm, no ST elevation. EMS transported the patient to Emergency Department for further evaluation. In ED, patient was hypertensive (155/65) with all other vitals WNL. Repeat EKG indicated NSR, low voltage QRS, with no ischemic appearing ST changes. ED physician administered 1L  saline bolus and 650mg Acetaminophen. Patient reported feeling better and was discharged with a differential diagnosis of vasovagal episode, electrolyte imbalance, and volume depletion.
Symptoms started around 2300 on 01/14/2021.  I experienced SOB; sharp and shooting pain throughout my extremities; dull body aches; nausea induced vomiting; dizziness; weakness.  I was unable to sleep throughout most of the night.  I used tylenol and ibuprofen for my symptoms which didnt seem to alleviate any of the symptoms during the night. Woke up on 01/15/2021 with a rash on my face.
Started getting dark urine and continued getting darker.  Went to Hospital emergency dept.  and was admitted on 1/31/2021.  Tested for Covid negative. Blood test revealed low red blood cells.  Urine tests and blood tests were inconclusive on 1/31.
Patient called on 10/29/13 and verbalized that her arm was red and hot and swollen near her injection site. She denied other sx. She was instructed to take BENADRYL and to report to the ER for worsening symptoms.
Shot given by mistake, no side effects or harm with giving the vaccine, parents notified and okay with event
This spontaneous report was received on 28-AUG-2017 from a registered nurse and refers to a 15-year-old female patient. No information about the patients' medical history, concurrent conditions, drug reactions or allergies and concomitant therapies was provided. The registered nurse reported that the female patient received GARDASIL 9 vaccine injection, intramuscularly (Dose/frequency was reported as: vaccine dose) (Site of vaccination, Lot number and expiration date were not reported) on 02-AUG-2017 for the indication of "HPV vaccine". It was the final dose in a three dose series. (The dates of vaccination with dose 1 and dose 2 were not reported.) The patient started to experience injection site soreness on an unspecified date between 03-AUG-2017 and 22-AUG-2017. On 23-AUG-2017, the patient reported that the pain is getting progressively worse. "It hurts to touch the arm or move it." No laboratory studies were performed. The patient sought medical attention reported as "yes, contacted physician." It was reported that treatment was given for the adverse experience. Treatment was not specified. The patient's present status was reported as not recovered. No further adverse experience to report. Product quality complaint was not involved. Additional information is not expected as no permission was given to request follow-up.
Information has been received concerning a pt who on 06/27/00 was vaccinated with one dose of varicella vaccine. On 06/30/00, the pt experienced difficulty breathing and sought medical attention at the physician office.
COVID-19 breakthrough infection. Pt received J&J on 03/09/2021.
My daughter spiked a low grade temp. of approx. 99.1 axillary. This was treated with alternating 5ml. doses of childrens Tylenol and Motrin. The fever waxed and waned in this range of 99.0-100.9 until going up to 103.4 at approx. 10:00 AM on Dec. 4th. patient was subsequently taken back to doctor for evaluation and sent home with instructions to discontinue the Tylenol and up the Motrin dose to 7mls. until the fever breaks or other symptoms occur ie., lethargy, seizures, etc. at which point we were instructed to take her into the hospital E.R.